In the BioHarmony Drug Report Database

"Preview" Icon

Ado-trastuzumab emtansine

Kadcyla (trastuzumab emtansine) is an antibody pharmaceutical. Trastuzumab emtansine was first approved as Kadcyla on 2013-02-22. It has been approved in Europe to treat breast neoplasms.

 

Trade Name

 

Kadcyla
 

Common Name

 

trastuzumab emtansine
 

ChEMBL ID

 

CHEMBL1743082
 

Indication

 

breast neoplasms
 

Drug Class

 

Monoclonal antibodies: humanized, tumors as target; maytansinoid derivatives

Image (chem structure or protein)

Ado-trastuzumab emtansine structure rendering